Molecular characterization, expression analysis, and role of ALDH3B1 in the cellular protection against oxidative stress

Free Radical Biology and Medicine

Volumn 49, Issue 9, 2010, Pages 1432-1443

  Marchitti, Satori A ^a   Brocker, Chad ^a   Orlicky, David J ^b   Vasiliou, Vasilis ^a  

^a Department of Pharmaceutical Sciences   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

4 Hydroxy 2 nonenal; Aldehyde dehydrogenase 3B1; Aldehyde toxicity; ALDH3B1; Enzyme kinetics; Free radicals; Lipid peroxidation; MRNA; Protein expression

Indexed keywords

4 HYDROXYNONENAL; ACETALDEHYDE; ALDEHYDE DEHYDROGENASE; BENZALDEHYDE; ESTER 4 NITROPHENYL ACETATE; HEXANAL; HYDROGEN PEROXIDE; MALONALDEHYDE; MENADIONE; OCTANAL; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL FRACTIONATION; CELL PROTECTION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CHROMATOGRAPHY; CLINICAL EVALUATION; CYTOTOXICITY; DETOXIFICATION; ENZYME INDUCTION; ENZYME KINETICS; GENE CONTROL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; KIDNEY; KIDNEY CELL; LIPID PEROXIDATION; LUNG; MOUSE; NONHUMAN; OVARY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PURIFICATION; SPECTROPHOTOMETRY; TESTIS;

ALDEHYDE OXIDOREDUCTASES; ALDEHYDES; ANIMALS; CYTOPROTECTION; CYTOSOL; EPITHELIAL CELLS; HEK293 CELLS; HUMANS; LIPID PEROXIDATION; LIVER; MICE; MICE, INBRED C57BL; OXIDANTS; OXIDATIVE STRESS; TRANSGENES;

EID: 77957145640     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2010.08.004     Document Type: Article

References (75)

1. Marchitti S.A., Brocker C., Stagos D., Vasiliou V. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin. Drug Metab. Toxicol. 2008, 4:697-720.
2. Lindahl R. Aldehyde dehydrogenases and their role in carcinogenesis. Crit. Rev. Biochem. Mol. Biol. 1992, 27:283-335.
3. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. USA 1996, 93:2696-2701.
4. Brooks P.J., Theruvathu J.A. DNA adducts from acetaldehyde: implications for alcohol-related carcinogenesis. Alcohol 2005, 35:187-193.
5. Shiraishi K., Naito K. Effects of 4-hydroxy-2-nonenal, a marker of oxidative stress, on spermatogenesis and expression of p53 protein in male infertility. J. Urol. 2007, 178:1012-1017.
6. Fuchs P., Loeseken C., Schubert J.K., Miekisch W. Breath gas aldehydes as biomarkers of lung cancer. Int. J. Cancer 2009, 126:2663-2670.
7. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 1991, 11:81-128.
8. 2+ dependent. Chem. Res. Toxicol. 2007, 20:887-895.
9. Vasiliou V., Pappa A., Estey T. Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism. Drug Metab. Rev. 2004, 36:279-299.
10. Mills P.B., Struys E., Jakobs C., Plecko B., Baxter P., Baumgartner M., et al. Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat. Med. 2006, 12:307-309.
11. Patel M., Lu L., Zander D.S., Sreerama L., Coco D., Moreb J.S. ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. Lung Cancer 2008, 59:340-349.
12. Sreerama L., Sladek N.E. Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Biochem. Pharmacol. 1993, 45:2487-2505.
13. Moreb J.S., Baker H.V., Chang L.J., Amaya M., Lopez M.C., Ostmark B., et al. ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol. Cancer 2008, 7:87.
14. Chang B., Liu G., Xue F., Rosen D.G., Xiao L., Wang X., et al. ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod. Pathol. 2009, 22:817-823.
15. Sladek N.E. Human aldehyde dehydrogenases: potential pathological, pharmacological, and toxicological impact. J. Biochem. Mol. Toxicol. 2003, 17:7-23.
16. Vasiliou V., Nebert D.W. Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. Hum. Genomics 2005, 2:138-143.
17. Graves P.R., Kwiek J.J., Fadden P., Ray R., Hardeman K., Coley A.M., et al. Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol. Pharmacol. 2002, 62:1364-1372.
18. Hsu L.C., Chang W.C., Yoshida A. Cloning of a cDNA encoding human ALDH7, a new member of the aldehyde dehydrogenase family. Gene 1994, 151:285-289.
19. Hsu L.C., Chang W.C., Yoshida A. Human aldehyde dehydrogenase genes, ALDH7 and ALDH8: genomic organization and gene structure comparison. Gene 1997, 189:89-94.
20. Vasiliou V., Bairoch A., Tipton K.F., Nebert D.W. Eukaryotic aldehyde dehydrogenase (ALDH) genes: human polymorphisms, and recommended nomenclature based on divergent evolution and chromosomal mapping. Pharmacogenetics 1999, 9:421-434.
21. Pappa A., Chen C., Koutalos Y., Townsend A.J., Vasiliou V. Aldh3a1 protects human corneal epithelial cells from ultraviolet- and 4-hydroxy-2-nonenal-induced oxidative damage. Free Radic. Biol. Med. 2003, 34:1178-1189.
22. Lassen N., Bateman J.B., Estey T., Kuszak J.R., Nees D.W., Piatigorsky J., et al. Multiple and additive functions of ALDH3A1 and ALDH1A1: cataract phenotype and ocular oxidative damage in Aldh3a1(-/-)/Aldh1a1(-/-) knock-out mice. J. Biol. Chem. 2007, 282:25668-25676.
23. Rizzo W.B. Sjogren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency. Mol. Genet. Metab. 2007, 90:1-9.
24. Rizzo W.B., Carney G. Sjogren-Larsson syndrome: diversity of mutations and polymorphisms in the fatty aldehyde dehydrogenase gene (ALDH3A2). Hum. Mutat. 2005, 26:1-10.
25. Marchitti S.A., Orlicky D.J., Vasiliou V. Expression and initial characterization of human ALDH3B1. Biochem. Biophys. Res. Commun. 2007, 356:792-798.
26. Benedetti A., Comporti M., Esterbauer H. Identification of 4-hydroxynonenal as a cytotoxic product originating from the peroxidation of liver microsomal lipids. Biochim. Biophys. Acta 1980, 620:281-296.
27. Bunting K.D., Townsend A.J. Protection by transfected rat or human class 3 aldehyde dehydrogenase against the cytotoxic effects of oxazaphosphorine alkylating agents in hamster V79 cell lines: demonstration of aldophosphamide metabolism by the human cytosolic class 3 isozyme. J. Biol. Chem. 1996, 271:11891-11896.
28. Manzer R., Qamar L., Estey T., Pappa A., Petersen D.R., Vasiliou V. Molecular cloning and baculovirus expression of the rabbit corneal aldehyde dehydrogenase (ALDH1A1) cDNA. DNA Cell Biol. 2003, 22:329-338.
29. Pappa A., Estey T., Manzer R., Brown D., Vasiliou V. Human aldehyde dehydrogenase 3A1 (ALDH3A1): biochemical characterization and immunohistochemical localization in the cornea. Biochem. J. 2003, 376:615-623.
30. Sheikh S., Ni L., Hurley T.D., Weiner H. The potential roles of the conserved amino acids in human liver mitochondrial aldehyde dehydrogenase. J. Biol. Chem. 1997, 272:18817-18822.
31. Bannai H., Tamada Y., Maruyama O., Nakai K., Miyano S. Extensive feature detection of N-terminal protein sorting signals. Bioinformatics 2002, 18:298-305.
32. Horten P., Park K.-J., Obayashi T., Nakai K. Protein subcellular localization prediction with WoLF PSORT 2006, [Abstract].
33. Emanuelsson O., Nielsen H., Brunak S., von H.G. Predicting subcellular localization of proteins based on their N-terminal amino acid sequence. J. Mol. Biol. 2000, 300:1005-1016.
34. Claros M.G., Vincens P. Computational method to predict mitochondrially imported proteins and their targeting sequences. Eur. J. Biochem. 1996, 241:779-786.
35. Small I., Peeters N., Legeai F., Lurin C. Predotar: a tool for rapidly screening proteomes for N-terminal targeting sequences. Proteomics 2004, 4:1581-1590.
36. Hirokawa T., Boon-Chieng S., Mitaku S. SOSUI: classification and secondary structure prediction system for membrane proteins. Bioinformatics 1998, 14:378-379.
37. Blom N., Gammeltoft S., Brunak S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J. Mol. Biol. 1999, 294:1351-1362.
38. Jordan M., Schallhorn A., Wurm F.M. Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res. 1996, 24:596-601.
39. Cox B., Emili A. Tissue subcellular fractionation and protein extraction for use in mass-spectrometry-based proteomics. Nat. Protoc. 2006, 1:1872-1878.
40. Lassen N., Pappa A., Black W.J., Jester J.V., Day B.J., Min E., et al. Antioxidant function of corneal ALDH3A1 in cultured stromal fibroblasts. Free Radic. Biol. Med. 2006, 41:1459-1469.
41. Messeguer X., Escudero R., Farre D., Nunez O., Martinez J., Alba M.M. PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics 2002, 18:333-334.
42. Farre D., Roset R., Huerta M., Adsuara J.E., Rosello L., Alba M.M., et al. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res. 2003, 31:3651-3653.
43. Wingender E., Chen X., Fricke E., Geffers R., Hehl R., Liebich I., et al. The TRANSFAC system on gene expression regulation. Nucleic Acids Res. 2001, 29:281-283.
44. Seng S., Avraham H.K., Birrane G., Jiang S., Avraham S. Nuclear matrix protein (NRP/B) modulates the nuclear factor (erythroid-derived 2)-like 2 (NRF2)-dependent oxidative stress response. J. Biol. Chem. 2010, 285:26190-26198.
45. Siow R.C., Ishii T., Mann G.E. Modulation of antioxidant gene expression by 4-hydroxynonenal: atheroprotective role of the Nrf2/ARE transcription pathway. Redox Rep. 2007, 12:11-15.
46. Beinke S., Ley S.C. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem. J. 2004, 382:393-409.
47. Gloire G., Legrand-Poels S., Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem. Pharmacol. 2006, 72:1493-1505.
48. Lindahl R., Petersen D.R. Lipid aldehyde oxidation as a physiological role for class 3 aldehyde dehydrogenases. Biochem. Pharmacol. 1991, 41:1583-1587.
49. King G., Holmes R.S. Human corneal aldehyde dehydrogenase: purification, kinetic characterisation and phenotypic variation. Biochem. Mol. Biol. Int. 1993, 31:49-63.
50. Vichai V., Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Protoc. 2006, 1:1112-1116.
51. Canuto R.A., Maggiora M., Trombetta A., Martinasso G., Muzio G. Aldehyde dehydrogenase 3 expression is decreased by clofibrate via PPAR gamma induction in JM2 rat hepatoma cell line. Chem. Biol. Interact. 2003, 143-144:29-35.
52. Li X.H., Kakkad B., Ong D.E. Estrogen directly induces expression of retinoic acid biosynthetic enzymes, compartmentalized between the epithelium and underlying stromal cells in rat uterus. Endocrinology 2004, 145:4756-4762.
53. Lassen N., Estey T., Tanguay R.L., Pappa A., Reimers M.J., Vasiliou V. Molecular cloning, baculovirus expression, and tissue distribution of the zebrafish aldehyde dehydrogenase 2. Drug Metab. Dispos. 2005, 33:649-656.
54. Liu Z.J., Sun Y.J., Rose J., Chung Y.J., Hsiao C.D., Chang W.R., et al. The first structure of an aldehyde dehydrogenase reveals novel interactions between NAD and the Rossmann fold. Nat. Struct. Biol. 1997, 4:317-326.
55. Kelson T.L., Secor M., Rizzo W.B. Human liver fatty aldehyde dehydrogenase: microsomal localization, purification, and biochemical characterization. Biochim. Biophys. Acta 1997, 1335:99-110.
56. Mitchell D.Y., Petersen D.R. Oxidation of aldehydic products of lipid peroxidation by rat liver microsomal aldehyde dehydrogenase. Arch. Biochem. Biophys. 1989, 269:11-17.
57. Evces S., Lindahl R. Characterization of rat cornea aldehyde dehydrogenase. Arch. Biochem. Biophys. 1989, 274:518-524.
58. Imami K., Sugiyama N., Kyono Y., Tomita M., Ishihama Y. Automated phosphoproteome analysis for cultured cancer cells by two-dimensional nanoLC-MS using a calcined titania/C18 biphasic column. Anal. Sci. 2008, 24:161-166.
59. Chen C.H., Budas G.R., Churchill E.N., Disatnik M.H., Hurley T.D., Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 2008, 321:1493-1495.
60. Mann C.J., Weiner H. Differences in the roles of conserved glutamic acid residues in the active site of human class 3 and class 2 aldehyde dehydrogenases. Protein Sci. 1999, 8:1922-1929.
61. Wang Y., Hu Y., Fang Y., Zhang K., Yang H., Ma J., et al. Evidence of epistasis between the catechol-O-methyltransferase and aldehyde dehydrogenase 3B1 genes in paranoid schizophrenia. Biol. Psychiatry 2009, 65:1048-1054.
62. Law A.J., Kleinman J.E., Weinberger D.R., Weickert C.S. Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Hum. Mol. Genet. 2007, 16:129-141.
63. Wang J.F., Shao L., Sun X., Young L.T. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord. 2009, 11:523-529.
64. Fukuda M., Kanou F., Shimada N., Sawabe M., Saito Y., Murayama S., et al. Elevated levels of 4-hydroxynonenal-histidine Michael adduct in the hippocampi of patients with Alzheimer's disease. Biomed. Res. 2009, 30:227-233.
65. Marchitti S.A., Deitrich R.A., Vasiliou V. Neurotoxicity and metabolism of the catecholamine-derived 3, 4-dihydroxyphenylacetaldehyde and 3, 4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol. Rev. 2007, 59:125-150.
66. Jinsmaa Y., Florang V.R., Rees J.N., Anderson D.G., Strack S., Doorn J.A. Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate. Chem. Res. Toxicol. 2009, 22:835-841.
67. Florang V.R., Rees J.N., Brogden N.K., Anderson D.G., Hurley T.D., Doorn J.A. Inhibition of the oxidative metabolism of 3, 4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal. Neurotoxicology 2006, 28:76-82.
68. Seitz H.K., Becker P. Alcohol metabolism and cancer risk. Alcohol. Res. Health 2007, 30:38-47.
69. Vasiliou V., Puga A., Nebert D.W. Negative regulation of the murine cytosolic aldehyde dehydrogenase-3 (Aldh-3c) gene by functional CYP1A1 and CYP1A2 proteins. Biochem. Biophys. Res. Commun. 1992, 187:413-419.
70. +/glucose cotransporter activity in renal proximal tubule cells. Am. J. Physiol. Renal Physiol. 2005, 288:F988-F996.
71. Che W., Qiu H., Liu G., Ran Y., Zhang H., Zhang L., et al. Oxidative damage of the extracts of condensate, particulate and semivolatile organic compounds from gasoline engine exhausts on testicles of rats. Bull. Environ. Contam. Toxicol. 2009, 83:42-47.
72. Hempel J., Kuo I., Perozich J., Wang B.C., Lindahl R., Nicholas H. Aldehyde dehydrogenase: maintaining critical active site geometry at motif 8 in the class 3 enzyme. Eur. J. Biochem. 2001, 268:722-726.
73. Marchitti S.A., Orlicky D.J., Brocker C., Vasiliou V. Aldehyde dehydrogenase 3B1 (ALDH3B1): immunohistochemical tissue distribution and cellular-specific localization in normal and cancerous human tissues. J. Histochem. Cytochem. 2010, 58:765-783.
74. Sladek N.E. Transient induction of increased aldehyde dehydrogenase 3A1 levels in cultured human breast (adeno)carcinoma cell lines via 5'-upstream xenobiotic, and electrophile, responsive elements is, respectively, estrogen receptor-dependent and -independent. Chem. Biol. Interact. 2003, 143-144:63-74.
75. Levonen A.L., Landar A., Ramachandran A., Ceaser E.K., Dickinson D.A., Zanoni G., et al. Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem. J. 2004, 378:373-382.